Video
IMbrave-150 and HIMALAYA: Clinical Trials of Immune Checkpoint Inhibitor Combinations in HCC
Author(s):
The panel reviews the HIMALAYA and IMbrave-150 clinical trials of checkpoint inhibitor combination therapy strategies in advanced HCC.
EP: 1.Overview of Hepatocellular Carcinoma Risk Factors
EP: 2.Review of Curative Treatment Strategies for HCC
EP: 3.Child-Pugh Scoring System and Liver Function Assessment
EP: 4.Therapy for Locally Advanced HCC
EP: 5.The Advent of Systemic Therapy for HCC
EP: 6.Immune Checkpoint Inhibitors in HCC
EP: 7.Combination Therapy with Immune Checkpoint Inhibitors for HCC
Now Viewing
EP: 8.IMbrave-150 and HIMALAYA: Clinical Trials of Immune Checkpoint Inhibitor Combinations in HCC
EP: 9.Immune Checkpoint Inhibitors and Their Effects on Liver Function
EP: 10.Real-World Evidence on Use of Immune Checkpoint Inhibitor Combinations and Clinical Trial Endpoints
EP: 11.Novel Strategies: Combining Systemic and Local Therapies
EP: 12.HCC International Clinical Trials
Related Videos
Related Content
